AlloVir (NASDAQ:ALVR) Stock Price Up 3.7%

AlloVir, Inc. (NASDAQ:ALVR) shot up 3.7% during trading on Tuesday . The stock traded as high as $0.83 and last traded at $0.79. 280,504 shares traded hands during mid-day trading, a decline of 76% from the average session volume of 1,187,760 shares. The stock had previously closed at $0.76.

Wall Street Analyst Weigh In

Separately, Bank of America cut AlloVir from a “buy” rating to an “underperform” rating in a research note on Tuesday, December 26th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $18.67.

AlloVir Stock Performance

The stock has a market cap of $90.87 million, a price-to-earnings ratio of -0.43 and a beta of 0.86. The company has a 50-day simple moving average of $0.74 and a two-hundred day simple moving average of $1.12.

AlloVir (NASDAQ:ALVR) last posted its quarterly earnings results on Friday, March 15th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.10). As a group, sell-side analysts predict that AlloVir, Inc. will post -0.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Diana Brainard sold 41,421 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $0.67, for a total transaction of $27,752.07. Following the transaction, the chief executive officer now directly owns 822,321 shares of the company’s stock, valued at approximately $550,955.07. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders have sold 103,945 shares of company stock valued at $71,175. 39.97% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ALVR. Wellington Management Group LLP grew its holdings in AlloVir by 50.4% in the 3rd quarter. Wellington Management Group LLP now owns 597,434 shares of the company’s stock valued at $1,284,000 after buying an additional 200,178 shares in the last quarter. FMR LLC grew its holdings in AlloVir by 1.7% in the 3rd quarter. FMR LLC now owns 9,682,460 shares of the company’s stock valued at $20,817,000 after buying an additional 160,918 shares in the last quarter. SG Americas Securities LLC acquired a new position in AlloVir in the 3rd quarter valued at $50,000. Jump Financial LLC acquired a new position in AlloVir in the 3rd quarter valued at $78,000. Finally, Clear Street Markets LLC acquired a new position in AlloVir in the 3rd quarter valued at $43,000. 66.05% of the stock is owned by institutional investors and hedge funds.

About AlloVir

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.